Combination Treatments Including CILO and/or FIR in Addition to SEMA Lead to Greater Improvements and Normalization of Cell Death Marker CK18 M30 in Patients With NASH

Conference Reports for NATAP

The Liver Meeting
Digital Experience
AASLD
November 13 - 16 - 2021


Combination Treatments Including CILO and/or FIR in Addition to SEMA Lead to Greater Improvements and Normalization of Cell Death Marker CK18 M30 in Patients With NASH

	AASLD 2021 Nov 12-15